Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 891-900 of 1761 for cancer

Edit search filters
  1. A Study To Evaluate The Effectiveness And Safety Of Panzyga In Patients With Chronic Lymphocytic Leukemia

    Rochester, MN

  2. Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients with Myelofibrosis

    Scottsdale/Phoenix, AZ

  3. Prospective Use Of Philips ISuite For Interventional Procedures

    Rochester, MN

  4. A Multi-Center Study Evaluating KTE-X19 In Pediatric And Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

    Rochester, MN

  5. Study To Evaluate Safety And Tolerability Of XmAb13676 In Patients With CD20-expressing Hematologic Malignancies

    Jacksonville, FL

  6. Inotuzumab Ozogamicin And Post-Induction Chemotherapy In Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, And B-LLy

    Rochester, MN

  7. First-in-Human Study Of KO-947 In Non-Hematological Malignancies

    Rochester, MN

  8. A Study To Assess The Safety And Antitumor Activity Of Genetically Engineered T Cells In NY-ESO-1 And/or LAGE-1a Positive Solid Tumors

    Jacksonville, FL, Rochester, MN

  9. Ibrutinib In Treating Minimal Residual Disease In Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy

    Jacksonville, FL

  10. Vorinostat, Temozolomide, or Bevacizumab in Combination with Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients with Newly Diagnosed High-Grade Glioma

    Rochester, MN

.

Mayo Clinic Footer